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Abstract
Background: Most patients with advanced breast cancer develop bone metastases, which cause pain, hypercalcemia,
fractures, nerve compression and paralysis. Chemotherapy causes further bone loss, and bone-specific treatments are only
palliative. Multiple tumor-secreted factors act on the bone microenvironment to drive a feed-forward cycle of tumor
growth. Effective treatment requires inhibiting upstream regulators of groups of prometastatic factors. Two central
regulators are hypoxia and transforming growth factor (TGF)- b. We asked whether hypoxia (via HIF-1a) and TGF-b signaling
promote bone metastases independently or synergistically, and we tested molecular versus pharmacological inhibition
strategies in an animal model.
Methodology/Principal Findings: We analyzed interactions between HIF-1a and TGF-b pathways in MDA-MB-231 breast
cancer cells. Only vascular endothelial growth factor (VEGF) and the CXC chemokine receptor 4 (CXCR4), of 16 genes tested,
were additively increased by both TGF-b and hypoxia, with effects on the proximal promoters. We inhibited HIF-1a and TGF-
b pathways in tumor cells by shRNA and dominant negative receptor approaches. Inhibition of either pathway decreased
bone metastasis, with no further effect of double blockade. We tested pharmacologic inhibitors of the pathways, which
target both the tumor and the bone microenvironment. Unlike molecular blockade, combined drug treatment decreased
bone metastases more than either alone, with effects on bone to decrease osteoclastic bone resorption and increase
osteoblast activity, in addition to actions on tumor cells.
Conclusions/Significance: Hypoxia and TGF-b signaling in parallel drive tumor bone metastases and regulate a common set
of tumor genes. In contrast, small molecule inhibitors, by acting on both tumor cells and the bone microenvironment,
additively decrease tumor burden, while improving skeletal quality. Our studies suggest that inhibitors of HIF-1a and TGF-b
may improve treatment of bone metastases and increase survival.
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Introduction
Breast cancers frequently metastasize to bone, where they disrupt
normalboneremodelingtocausebone destruction,pain,pathologic
fracture, hypercalcemia, and nerve compression [1]. Besides
conventional radiation and chemotherapy, bisphosphonates are
the only treatment available for patients with bone metastases.
These drugs decrease skeletal morbidity and provide palliative relief
but no cure [1]. Bone is a unique microenvironment in which breast
cancer thrives. Growth factors, such as transforming growth factor-
b (TGF- b) are stored in the mineralized bone matrix. Breast
cancers that metastasize to bone secrete factors, such as parathyroid
hormone-related protein (PTHrP) and interleukin-11 (IL-11), that
stimulate osteoclastic bone destruction and the release and
activation of growth factors immobilized in the bone matrix. These
factors in turn act on tumor cells to promote a feed-forward cycle of
tumor growth and bone destruction which contributes to the
incurability of bone metastases [2]. Hypoxia and high concentra-
tions of TGF-b in the bone microenvironment enhance tumor
production of factors that drive the feed-forward cycle of bone
metastasis. We asked whether the hypoxia and TGF-b signaling
pathways have additive or synergistic effects to promote breast
cancer bone metastasis to determine if combined treatment with
inhibitors of these pathways could be used to treat bone metastases.
Bone is the largest storehouse of TGF-b in the body. TGF-b has
complex effects in cancer and is a growth suppressor early in
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growth inhibition by TGF-b and express prometastatic genes in
response [3]. TGF-b signaling pathway is activated when TGF-b
binds to the TGF-b type II receptor (TbRII) and promotes
dimerization with and activation of the TGF-b type I receptor
(TbRI) [3]. TbRI contains a kinase domain which phosphorylates
the receptor-associated Smads, Smad2 and Smad3. These factors
bind to Smad4 forming a heteromeric Smad complex which
translocates to the nucleus and mediates gene transcription by
binding to Smad binding elements (SBEs) in the promoters of
target genes [4].
TGF-b has an additional role in cancer to promote bone
metastasis by regulating many of the tumor-secreted factors that
stimulate tumor growth and bone destruction [5] (Table 1), such as
PTHrP [6], IL-11, connective tissue growth factor (CTGF), the
CXC chemokine receptor 4 (CXCR4), and others [7–10].
Previous studies using mouse models have shown that blockade
of TGF-b signaling in MDA-MB-231 breast carcinoma cells by
stable expression of a dominant-negative TbRII reduced bone
metastases and increased survival [6]. Expression of a constitu-
tively active TbRI reversed this effect, resulting in increased bone
metastases and decreased survival [6]. Inhibition of TGF-b
signaling by knockdown of Smad4 [11,12], overexpression of the
inhibitory Smad7 [13], or treatment with pharmacologic inhibi-
tors, such as SD-208 [14], an ATP-competitive inhibitor of the
TbRI kinase or other TGF-b inhibitors [15–18] decreased bone
metastases in animal models.
Bone is a hypoxic microenvironment (pO2 between 1–7%) [19],
which increases growth of metastatic tumor cells adapted for
surviving in conditions of low O2. Breast cancers and other solid
tumors are susceptible to hypoxia because they proliferate and
outgrow vascular supplies of oxygen and nutrients [20]. Tumor
hypoxia causes radio- and chemotherapeutic resistance, which
may contribute to the incurability of bone metastases [21].
Hypoxia activates signaling through hypoxia-inducible factor
(HIF)-1a, which is overexpressed in many cancers, including
breast. HIF-1a expression correlates with increasing tumor grade,
invasion, and metastasis [22]. In conditions of high oxygen, HIF-
1a is hydroxylated and targeted for proteasomal degradation by
the von Hippel Lindau tumor suppressor. When oxygen is
limiting, HIF-1a heterodimerizes with HIF-1b in the nucleus
and mediates the transcription of hypoxia-regulated target genes
[20,23].
Many bone metastases genes that are regulated by TGF-b are
also regulated by hypoxia (Table 1), including those identified by
Kang et al. to comprise a bone-metastatic gene signature in breast
cancer cells: CTGF, CXCR4, IL-11, and MMP-1 [8,13,24–26].
These genes code for proteins that regulate different steps of the
metastatic cascade: invasion, homing, angiogenesis and osteolysis.
Breast cancer cells express there and many other prometastatic
genes. Thus, therapeutic targeting of individual proteins is unlikely
to cure breast cancer bone metastases. Inhibitors of HIF-1a or
TGF-b, which act upstream of multiple target genes, may be more
effective and several are under investigation in phase I and II
clinical trials for various cancers [14,15,27–31].
We investigated interactions between the hypoxia and TGF-b
signaling pathways in vitro by examining bone-metastatic MDA-
MB-231 breast cancer cells for changes in TGF-b and hypoxia-
stimulated gene expression of 16 candidate genes. Of these, only
vascular endothelial growth factor (VEGF) and CXCR4, showed
additive responses to TGF-b and hypoxia, suggesting limited
crosstalk between TGF-b and hypoxia signaling pathways in
breast cancer cells. In vitro analyses, however, may not accurately
represent in vivo function. Therefore, we used a mouse model of
bone metastasis to assess global crosstalk between the hypoxia and
TGF-b signaling pathways in vivo. In this model, the MDA-MB-
231 breast cancer cell line reliably forms osteolytic bone lesions in
nude mice when inoculated into the left cardiac ventricle. We
tested the effects TGF-b and hypoxia on bone metastases in this
model by genetic and pharmacologic approaches. In the first
approach, we used genetic methods of shRNA knockdown and
dominant-negative expression to specifically target the tumor cells.
Genetic inhibition of HIF-1a and TGF-b signaling pathways in
MDA-MB-231 cells significantly decreased osteolysis and en-
Table 1. Regulation of bone metastases genes by hypoxia and TGF-b.
Gene Type Gene Hypoxia Both TGF-b
Bone Metastatic Genes (Kang et al. 2003) CTGF 34
* 66 3 2
*
CXCR4 87
* 15 5
*
OPN 61
* 43 1 4
*
IL-11 5 0 171
*
MMP-1 24
* 72 1 6
*
Tumor-Secreted Factors PTHrP 9 1 193
*
IL-6 384
* 20
* 2974
*
IL-8 200
* 68 1 6
*
Endothelin-1 590
* 17
* 313
*
Adrenomedullin 140
* 33 8
*
VEGF 3152
* 108
* 1182
*
PDGF 128
* 23 1823
*
Stanniocalcin 12
* 03
Thrombospondin 59
* 93 1 4
*
Cyr61 17
* 12 8
*
Number of hits returned from a Pubmed literature search conducted in February 2009 for the name of each gene with the keywords TGF-b and/or hypoxia. Asterisk (
*)
indicates genes for which regulation by these pathways has been published.
doi:10.1371/journal.pone.0006896.t001
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inhibition of HIF-1a and TGF-b in the tumor cells had no
additional effect, suggesting parallel roles for hypoxia and TGF-b
signaling in tumor cells. This approach provided proof of principle
for the tumor autonomous effects of HIF-1a and TGF-b signaling
in bone metastases, but it is not readily translatable to the clinic. In
a second pharmacologic approach, we inhibited HIF-1a and
TGF-b signaling systemically using small molecule inhibitors to
target both the tumor cells and the bone microenvironment.
Inhibition of HIF-1a or TGF-b with these inhibitors also
decreased osteolysis, reduced tumor burden, and enhanced
survival of mice with bone metastases. In contrast to the genetic
models, combined pharmacologic inhibition produced an addi-
tional decrease in tumor burden compared to either alone.
Systemic inhibition of HIF-1a and TGF-b signaling also had
independent effects on bone to decrease osteoclast and increase
osteoblast activity. Thus, combined systemic inhibition of HIF-1a
and TGF-b signaling is more beneficial than either alone due to
activity on the tumor cells and the bone microenvironment.
Results
Hypoxia induces HIF-1a expression in bone metastatic
cancer cell lines in vitro and in vivo at sites of MDA-MB-
231 breast cancer bone metastases
Three bone metastatic cancer cell lines: MDA-MB-231 breast
cancer, PC-3 prostate cancer, and 1205Lu melanoma cells, were
tested for hypoxic responsiveness by culture in 20% or 1% O2 for
6 h. Western blot analysis showed induction of HIF-1a expression
under hypoxic conditions, which was blocked by treatment with
the HIF-1a inhibitor 2-methoxyestradiol (2ME2) [32–34]
(Figure 1A). We next determined whether MDA-MB-231 breast
cancer bone metastases are hypoxic in vivo by Hypoxyprobe
TM-1
staining [35–38]. Mice with MDA-MB-231 bone metastases were
injected 2 h prior to euthanasia with pimonidazole, which forms
insoluble protein adducts in hypoxic cells. Staining was detected in
bone metastases sections from pimonidazole-labeled mice but not
in control animals (Figure 1B). Staining for HIF-1a protein was
detected in serial bone metastases sections, at sites adjacent to
Figure 1. Hypoxia induces HIF-1a in bone-metastatic cancer cells in vitro and in bone metastases in vivo. (A) MDA-MB-231, PC-3 and
1205Lu cells were treated with 2ME2 and cultured 6 1% O2 during 6 h. Protein lysates from the treated cells were analyzed for HIF-1a protein
expression by Western blotting. a-tubulin was used as loading control. (B) Representative demineralized bone sections from mice with MDA-MB-231
bone metastases stained for tumor hypoxia with Hypoxyprobe
TM-1 (HP), with an antibody against HIF-1a, or with hematoxylin and eosin (H&E).
Arrows indicate HIF-1a positive nuclei. Images are at 2006magnification with scale bar equal to 100 mm, inset is at 6306magnification with scale bar
equal to 50 mm. Staining without primary antibody was used as negative control.
doi:10.1371/journal.pone.0006896.g001
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for hypoxia-induced HIF-1a in bone metastases.
Hypoxia and TGF-b additively increase prometastatic
factors VEGF and CXCR4
A literature search for bone metastatic genes combined with the
keywords hypoxia or TGF-b, found that many were regulated by
the two pathways (Table 1). MDA-MB-231 cells treated 6 TGF-
b1 (5 ng/mL) and 6 1% O2 for 24 h were then surveyed by semi-
quantitative RT-PCR for changes in mRNA expression of
candidate TGF-b and hypoxia-regulated genes selected from
Table 1: VEGF; CXCR4; PTHrP; IL-6, 8, 11; and CTGF. We
also measured the expression of components of the two signaling
pathways: HIF-1a, prolyl hydroxylase 2 (PHD2), TGF-b1,
Smads2, 3, 4 and 7, Ski and SnoN. Many genes were increased
by TGF-b or hypoxia alone (data not shown) while only 2 of the 16
surveyed genes, VEGF and CXCR4, were increased by both
TGF-b and 1% O2 alone (Figure 2A). VEGF mRNA expression
was additively increased by TGF-b and 1% O2; however, there
was no additional increase in CXCR4 mRNA expression with
Figure 2. Hypoxia and TGF-b increase VEGF and CXCR4 mRNA expression and promoter activity. (A) MDA-MB-231 cells were cultured 6
TGF-b (5 ng/mL) 6 1% O2 during 24 h and total RNA was extracted. VEGF and CXCR4 mRNA expression (mean 6 SEM) was measured by semi-
quantitative RT-PCR (n=3). * P,0.05, *** P,0.005, **** P,0.001, using an unpaired Student’s t test. (B) HepG2 hepatocarcinoma cells co-transfected
with a renilla luciferase plasmid (phRL-CMV) and a pGL3 plasmid containing a fragment of the human VEGF (3.3 kb) or CXCR4 (2.6 kb) promoter, or
the TGF-b-sensitive (CAGA)9 promoter were treated 6 TGF-b (5 ng/mL) and 6 1% O2 during 24 h before measuring dual-luciferase activity. (C) MDA-
MB-231 breast cancer cells were transfected with a pGL3 plasmid containing the human VEGF or CXCR4 promoter and the phRL-CMV plasmid, as well
as plasmids to overexpress HIF-1a and/or Smad2, 3 and 4. Cells were treated 6 TGF-b (5 ng/mL) 6 1% O2 during 24 h before measuring dual-
luciferase activity. Results are expressed as the mean 6 SEM (n=3) of the relative luciferase activity. * P,0.05, ** P,0.01, *** P,0.005, **** P,0.001,
using an unpaired Student’s t test.
doi:10.1371/journal.pone.0006896.g002
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CXCR4 promoters by TGF-b and hypoxia was analyzed by dual-
luciferase assay in HepG2 cells transfected with a pGL3-luciferase
reporter vector containing either a 3.3 kb human VEGF promoter
fragment [39] or a 2.6 kb human CXCR4 promoter fragment
[40,41]. A (CAGA)9 promoter-luciferase construct containing nine
tandemly-repeated Smad-binding elements (SBEs) was used as
positive control for TGF-b activation. Dual-luciferase activity was
assayed after a 24 h-treatment 6 TGF-b1 and 6 1% O2. VEGF
and CXCR4 promoter activities were increased by treatment with
TGF-b or hypoxia alone (Figure 2B). Combined treatment
additively increased VEGF and CXCR4 promoter activation.
(CAGA)9 promoter activity was increased only by treatment with
TGF-b, demonstrating that hypoxia does not directly regulate
TGF-b/Smad signaling. These results suggest that crosstalk
between the hypoxia and TGF-b signaling pathways regulates
VEGF and CXCR4 mRNA expression and promoter activation.
Overexpression of HIF-1a and Smads increases VEGF and
CXCR4 expression
Next we tested whether HIF-1a and Smads mediate promoter
activationinresponsetohypoxiaandTGF-b.HIF-1aorSmads2,3,
and 4 were overexpressed in MDA-MB-231 cells cotransfected with
either the VEGF or CXCR4 promoter-luciferase plasmids. Dual-
luciferase activity was assayed after a 24 h-treatment with TGF-b1
and 1% O2. Overexpression of either HIF-1a or Smads increased
VEGF and CXCR4 promoter activity in response to TGF-b and
hypoxia (Figure 2C). Coexpression of HIF-1a and Smads together
resulted in a 10-fold increase in VEGF and CXCR4 promoter
activities in the presence of TGF-b and hypoxia, suggesting that
VEGF and CXCR4 transcriptional responses to hypoxia and TGF-
b are mediated through HIF-1a and Smads, respectively.
TGF-b and hypoxia interact to regulate VEGF and CXCR4
transcription
To identify promoter regions targeted by TGF-b and hypoxia
signaling, constructs with 59-deletion of the promoter, ranging in
size from 3.3 kb to 1.8 kb for VEGF and 2.6 kb to 1.0 kb for
CXCR4, were tested for TGF-b and hypoxia responsiveness by
dual-luciferase assay. VEGF promoter response to TGF-b and
hypoxia was blocked by deletion of bases 21181 to 2843, while
deletion of bases 22216 to 2953 blocked CXCR4 responsiveness
(Figure 3A). These results suggest that transcriptional activation by
TGF-b and hypoxia is localized within 300 base pairs in the
VEGF promoter and in a 1.2 kb region for CXCR4.
Promoter sequences were scanned for putative hypoxia response
elements (HREs) and SBEs using the consensus sequences 59-
RCGTG-39 and 59-CAGAC-39, respectively. HREs and SBEs
found in close proximity within the promoter regions identified
above were mutated by site-directed mutagenesis (Figure 3B).
TGF-b and hypoxia responsiveness were assayed using dual-
luciferase. In the VEGF promoter, mutation of HRE (2975/
2970) and SBEs (2992/2988) and (2797/2793) decreased the
response to TGF-b and 1% O2 (Figure 3C). The combined
mutation of the HRE and one of the SBE nearly abolished
promoter activity. Mutation of HRE (21316/21310) in the
CXCR4 promoter blocked additive responses to TGF-b and
hypoxia, while mutation of putative SBEs had little or no effect
(Figure 3C). These data suggest that both TGF-b and hypoxia
regulate VEGF promoter activity, while only hypoxia regulates
CXCR4 promoter activity. The promoter may contain additional
non-identified SBEs that mediate its response to TGF-b.
HIF-1a knockdown in MDA-MB-231 breast cancer cells
decreases osteolytic bone metastases and improves
survival in a mouse model
We further examined hypoxic responses of MDA-MB-231 cells
in vitro by stable knockdown of HIF-1a. The cells were transfected
with a plasmid expressing an shRNA targeting HIF-1a. Single cell
clones were isolated and stability of the knockdown was tested after
cultivating the cells for 60 days in absence of antibiotic. Two
clones (shHIF#3 and #11) with .90% decrease of HIF-1a
mRNA and undetectable levels of HIF-1a protein were further
analyzed (Figure 4A). Two control shRNA clones (shNT#3 and
#7) had HIF-1a mRNA expression similar to parental cells and
were used as controls. The clones were also analyzed by semi-
quantitative RT-PCR for changes in mRNA expression following
TGF-b1 and 1% O2 treatment for 24 h. TGF-b- and hypoxia-
induced VEGF and CXCR4 mRNA expression was significantly
decreased in the shHIF clones compared to parental and shNT
cells (Figure 4B). Secreted VEGF-A protein, measured by ELISA
(Figure 4C), and CXCR4 protein, measured by flow cytometry
(Figure 4D), were also decreased. The results demonstrate that
knockdown of HIF-1a blocks expression of prometastatic factors
VEGF and CXCR4 in MDA-MB-231 cells. An MTT assay
showed no difference in proliferation for any of the shHIF or
shNT clones compared to parental MDA-MB-231 cells in
normoxic conditions. Proliferation of each clone was decreased
by culture in hypoxic compared to normoxic conditions; however,
there was no difference among the clones (data not shown).
We tested the effect of HIF-1a knockdown in vivo using a mouse
model of bone metastases. Female nude mice (4 weeks old) were
inoculated in the left cardiac ventricle with parental MDA-MB-231
cells or one of the four different clones: shNT#3 and #7 controls,
or shHIF#3a n d#11 HIF-1a knockdown clones (n=12 per
group). Osteolytic lesion area on x-ray was decreased in mice with
shHIF knockdown bone metastases compared to those with controls
of parental or shNT bone metastases (P,0.001 for shHIF#3a n d
P,0.01 for shHIF#11 compared to parental or shNT clones)
(Figure 5A–B). HIF-1a knockdown in bone metastatic cells also
significantly improved survival of mice compared to control animals
(Figure 5C). A secondary endpoint for this survival experiment was
tumor burden, which was analyzed by quantitative histomorphom-
etry. We observed no difference in tumor burden at time of death
for mice with shHIF bone metastases compared to those with
parental or shNT bone metastases (Figure 5D–E). We were unable
to statistically compare tumor burden in mice from these groups at
the same time point, as mice with shHIF bone metastases lived
longer than the parental or shNT controls.
Staining for HIF-1a in bone metastases tumor sections was
decreased in shHIF bone metastases compared to parental and
shNT controls, confirming the stability of HIF-1a knockdown
throughout the in vivo experiment (Figures 6A–B). Since HIF-1a
knockdown in vitro resulted in decreased mRNA expression of the
angiogenic factor VEGF, we analyzed tumor angiogenesis in vivo
by staining for the endothelial cell marker CD31. The number of
vessels/tumor area was significantly decreased in shHIF bone
metastases compared to parental and shNT bone metastases
(Figure 7A–B). These data suggest that knockdown of HIF-1a in
tumor cells decreases bone metastases by suppressing tumor
secretion of proangiogenic factors and blocking vessel formation.
HIF-1a knockdown or TGF-b blockade in tumor cells
reduces bone metastases and improves survival in vivo
To evaluate the effect of single and combined inhibition of HIF-
1a and TGF-b specifically in tumor cells in vivo, we generated a
Hypoxia and Bone Metastasis
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HIF-1a shRNA alone or in combination with a dominant-negative
TGF-b type II receptor (DNRII). Knockdown of HIF-1a mRNA
and protein was confirmed by semi-quantitative RT-PCR and
Western blot (Figure 8A–B). Blockade of TGF-b signaling in the
DNRII expressing clones was confirmed by decreased phosho-
Smad2 on Western blot (Figure 8C) and decreased (CAGA)9
promoter activation in response to TGF-b (Figure 8D). TGF-b
and 1% O2-stimulated VEGF and CXCR4 mRNAs were
decreased in the DNRII and DNRII/shHIF clones compared to
parental control (Figure 8E). In vivo, mice inoculated with the
DNRII/shHIF-1a clones had decreased osteolytic lesion area and
improved survival compared to mice with bone metastases caused
by parental or DNRII cell lines (data not shown). DNRII/
shHIF#22 and DNRII/shNT#2 control clones were selected for
a subsequent experiment in which we directly compared the effect
of HIF-1a knockdown alone or combined with TGF-b blockade in
vivo. Female nude mice (n=12 per group) were inoculated in the
left cardiac ventricle with one of the six MDA-MB-231 cell lines:
parental, shNT#3, shHIF#3, DNRII, and DNRII/shNT#2o r
DNRII/shHIF#22. Mice were followed by radiography for the
development of osteolytic lesions. Lesion area on x-ray was
decreased by knockdown of HIF-1a (shHIF#3) or blockade of
TGF-b (DNRII or DNRII/shNT#2) (P,0.001 shHIF#3 and
DNRII compared to parental and P,0.05 shHIF#3 compared to
shNT#3) (Figure 9A–B). Combined inhibition of TGF-b and
HIF-1a (DNRII/shHIF#22) had no additional effect on osteol-
ysis. Survival of mice with MDA-MB-231 bone metastases was
Figure 3. Hypoxia and TGF-b increase VEGF and CXCR4 transcription through proximal promoter response elements. (A) HepG2 cells
were transfected with pGL3 plasmids containing full-length for 59-deleted fragments of the human VEGF or CXCR4 promoter and the phRL-CMV
plasmid. Cells were treated 6 TGF-b (5 ng/mL) 6 1% O2 during 24 h before measuring dual-luciferase activity. Results are expressed as the mean 6
SEM (n=3) of the relative luciferase activity, analyzed using an unpaired Student’s t test. (B) Schematic representation of wild-type (WT), HRE-mutant
(mH1) and SBE-mutant (mS1 or mS2) VEGF and CXCR4 promoters. One to three nucleotides (underlined, bold letters) within HRE and SBEs were
substituted as indicated. (C) HepG2 cells were transfected with pGL3 plasmids containing a wild-type VEGF or CXCR4 promoter or promoters with
mutations to the HRE or SBE and the phRL-CMV plasmid. Cells were treated 6 TGF-b (5 ng/mL) 6 1% O2 during 24 h before measuring dual-
luciferase activity. Results are expressed as the mean 6 SEM (n=3) of the relative luciferase activity, analyzed using an unpaired Student’s t test. *
P,0.05, ** P,0.01, *** P,0.005, **** P,0.001.
doi:10.1371/journal.pone.0006896.g003
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(Figure 9C). Combined inhibition of these pathways yielded no
further improvement in survival. Quantitative histomorphometry
for tumor burden was analyzed as a secondary endpoint for this
experiment. There was no difference in tumor burden at time of
death in the mice with shHIF, DNRII, or shHIF/DNRII bone
metastases compared to the control groups (Figure 9D), which was
not unexpected because the survival of these mice was increased.
To determine if the observed effects were bone specific, we
analyzed tumorgrowth followinginoculationof these clones into the
mammary fat pad. Tumor take and rate of growth were similar for
the parental, DNRII, and DNRII/shNT#2 clones, but decreased
in the shHIF#3 and DNRII/shHIF#22 clones (data not shown).
The data suggest that HIF-1a knockdown may decrease bone
metastases by inhibiting tumor cell proliferation rather than
increasing apoptosis, as TUNEL staining of bone metastases tumor
sectionsdemonstratednodifferenceintumorcellapoptosisinshHIF
compared to parental or shNT bone metastases (data not shown).
Pharmacologic inhibition of HIF-1a with 2ME2 decreases
osteolytic lesion area and tumor burden in a preventive
model of bone metastasis
The preceding studies provide proof of principle that the HIF-
1a and TGF-b signaling pathways in breast cancer cells promote
skeletal metastases. Molecular blockade of either pathway prevents
tumor growth in bone although the effects were not additive. To
determine whether systemic inhibition of these pathways in tumor
and host cells provided similar benefit, we used a pharmacologic
approach with the HIF-1a inhibitor, 2-methoxyestradiol (2ME2)
[32–34]. We showed that 2ME2 decreases HIF-1a protein
expression in MDA-MB-231 breast cancer cells in vitro
(Figure 1A). 2ME2 was also previously shown to decrease
osteolysis in a 4T1 breast cancer metastasis model [42]. Here,
we tested a nanocrystalline dispersion formulation with improved
bioavailability [43] in a prevention model for breast cancer bone
metastases. Drug treatment (150 mg/kg i.p.) was initiated two days
prior to the inoculation of tumor cells and continued daily during
the experiment. Female nude mice (n=15 per group) were
inoculated into the left cardiac ventricle with MDA-MB-231 cells
and the development of osteolytic lesions was followed by
radiography. Animals were euthanized at the same time point in
order to compare tumor burden between the vehicle and 2ME2
treated groups.
Preventive treatment with 2ME2 significantly reduced osteolysis
area (P,0.01) (Figure 10A) with a consistent decrease in tumor
burden by histomorphometric analyses (P,0.005) (Figure 10B).
Staining for nuclear HIF-1a in the tumor cells was significantly
decreased in mice treated with 2ME2 compared to vehicle-treated
mice, confirming that the 2ME2 treatment was effective in vivo
Figure 4. Knockdown of HIF-1a inhibits VEGF and CXCR4 mRNA and protein expression in vitro. (A) MDA-MB-231 parental cells (P) or
cells transfected with a pLKO.1 vector expressing a non-target shRNA (shNT#3 and #7) or an shRNA against HIF-1a (shHIF#3 and #11) were
cultured 6 1% O2 during 6 h. Total RNA was extracted and mean 6 SEM expression of HIF-1a was measured using semi-quantitative RT-PCR (n=3).
Proteins were extracted from treated cells and HIF-1a level was assayed by Western-blotting, a-tubulin was used as loading control. * P,0.05, using
an unpaired Student’s t test. (B) Parental (P) cells and shNT and shHIF clones were treated 6 TGF-b (5 ng/mL) 6 1% O2 for 24 h. Total RNA was
extracted and mean 6 SEM VEGF and CXCR4 expression was measured using semi-quantitative RT-PCR (n=3). * P,0.05, ** P,0.01, **** P,0.001,
using an unpaired Student’s t test. (C) MDA-MB-231 parental (P) cells and clones were treated 6 TGF-b (5 ng/mL) 6 1% O2 and conditioned media
were collected 24 h later. VEGF-A levels were measured by ELISA assay. Results are expressed as mean 6 SEM nanograms VEGF-A per 10
6 cells. ****
P,0.001, using an unpaired Student’s t test. (D) MDA-MB-231 parental (P) cells and clones were treated 6 1% O2 for 24 h and then analyzed by flow
cytometry for CXCR4 protein expression. Results are reported as the percentage of maximal CXCR4 expression.
doi:10.1371/journal.pone.0006896.g004
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mice as demonstrated by Hypoxyprobe
TM-1 staining (Figure 10D).
The data indicate that 2ME2 effectively inhibits HIF-1a
expression within the tumor microenvironment.
2ME2 increases bone mass by increasing osteoblasts and
inhibiting osteoclasts in bone unaffected by tumor
To determine the effects of 2ME2 in normal bone, mice were
treated with 2ME2 (150 mg/kg i.p) daily for 4 weeks. Bone
mineral density (BMD) was measured weekly by DXA throughout
the experiment. Mice treated with 2ME2 had significantly
increased BMD at the tibia (P,0.001) and femur (P,0.05), but
not at the spine (Figure 11A). Trabecular bone was increased at
the distal femur and proximal tibia by 2ME2 treatment, as
demonstrated by histology of bones from the mice (Figure 11B).
To determine if alterations in bone resorption or bone formation
were responsible for the increase bone mass, we counted osteoclast
and osteoblast on histologic sections of bone using histomorpho-
metric analysis. Osteoclast number per bone surface was decreased
(P=0.0077, Figure 11C–D), while osteoblast number was
increased (P=0.0002, Figure 11E–F) in the 2ME2-treated mice
compared to vehicle-treated controls. The data suggest that 2ME2
may inhibit bone metastases through direct effects on bone by
inhibiting osteoclast and increasing osteoblast activity, in addition
to its effects on tumor cells.
Pharmacologic inhibition of TbRI reduces the
development and progression of breast cancer
metastases to bone and improves survival
To compare single systemic inhibition of HIF-1a with inhibition
of TGF-b signaling, we tested the efficacy of SD-208, a small
molecule inhibitor of TbRI kinase, in a prevention model of bone
metastasis. Mice were treated with either 0.3 or 1.0 mg/mL SD-
208 in the drinking water, beginning two days prior to tumor
inoculation and continuing for the duration of the study. Both
doses of SD-208 significantly reduced the osteolytic lesions
detectable on radiography (Figure 12A–B). Histomorphometric
analysis of total tumor area showed a similar reduction in tumor
Figure 5. Knockdown of HIF-1a decreases osteolytic lesions and improves survival of mice in vivo. (A) Representative x-ray images from
hindlimbs of mice 4 weeks post inoculation with MDA-MB-231 parental, shNT and shHIF cells. Arrows indicate osteolytic lesions. (B) Osteolytic lesion
area measured on radiographs of hindlimbs and forelimbs of mice with bone metastases. Results are expressed as the mean area 6 SEM per mouse
(n=5–10 per group). { P,0.01 and * P,0.001 compared to parental or shNT clones using a two-way ANOVA with a Bonferroni post-test at 4 weeks.
(C) Kaplan-Meyer analysis of mouse survival. * P,0.05 shHIF#3 compared to Parental or shNT clones, { P,0.005 and { P=0.089 shHIF#11
respectively compared to Parental and shNT#7 using a Logrank test. (D) Representative histology of femurs with tumor indicated by arrows. Scale
bar equal to 500 mm. (E) Tumor burden in hindlimbs was measured by quantitative histomorphometry. Results are expressed as the mean 6 SEM
area per bone. A one-way ANOVA with a Newman-Keuls multiple comparison test showed no significant differences (N.S.) between groups.
doi:10.1371/journal.pone.0006896.g005
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in a dose-dependent increase in median survival compared to
control animals (25, 35 and 37 days for vehicle, 0.3 and 1.0 mg/
mL SD-208, respectively, p=0.008) (Figure 12E).
Combined inhibition of HIF-1a and TGF-b with small
molecule inhibitors additively decreases bone
metastases in mice
Next, we tested whether combined systemic inhibition of HIF-
1a with 2ME2 and TGF-b with a TbRI kinase inhibitor SD-208
[14,31] provided additional therapeutic benefit in a therapeutic
model of breast cancer bone metastasis. Mice were inoculated with
MDA-MB-231 cells and were followed by x-ray for the
development of bone metastases. Treatment was initiated when
osteolytic lesions were observed on x-ray at 12 days post tumor
inoculation and continued daily during the experiment. Mice
(n=15/group) were randomized to one of four treatment groups:
vehicle, 2ME2 alone (150 mg/kg i.p.), SD-208 alone (60 mg/kg
by oral gavage), or 2ME2 and SD-208 combined. To control for
the effects of the different methods of drug administration, all mice
received daily i.p. injection with either 2ME2 or PBS vehicle and
oral gavage with either SD-208 or 1% methylcellulose vehicle.
Treatment with either 2ME2 or SD-208 alone significantly
decreased x-ray lesion area (P,0.01 SD-208 and P,0.001
2ME2 compared to vehicle) (Figure 13A), which was further
decreased with combined treatment (P,0.01 and P,0.05 SD-208
+ 2ME2 compared to SD-208 and 2ME2, respectively). Mice were
euthanized at the same time point and histomorphometric analysis
showed a corresponding decrease in tumor burden in the femora,
tibiae and humeri of 2ME2 and SD-208-treated animals
compared to vehicle-treated mice (Figure 13B–C). Tumor burden
was further decreased by treatment with SD-208 and 2ME2
combined, compared to SD-208 alone (P,0.05) (Figure 13B–C). A
trend towards an additional decrease with combined treatment
compared to 2ME2 treatment alone did not reach significance.
We observed similar effects in a preventive model for breast
cancer bone metastasis (data not shown). In this model, treatment
with 2ME2 and SD-208 was initiated two days prior to tumor
inoculation. Tumor burden was significantly decreased by
combined treatment compared to SD-208 alone, with a trend
towards an additional decrease compared to 2ME2. Together,
these studies suggest that combined pharmacologic targeting of
HIF-1a and TGF-b effectively reduces the development and
progression of osteolytic bone metastases greater than either alone.
Combined treatment with 2ME2 and SD-208 decreases
osteoclast number at sites of bone metastases
We hypothesized that combined 2ME2 and SD-208 addition-
ally decrease bone metastases by targeting other cells in the bone
metastatic microenvironment in addition to tumor cells. Because
breast cancer cells secrete factors which stimulate osteoclast
formation and bone resorption in osteolytic metastases, we
Figure 6. Knockdown of HIF-1a in MDA-MB-231 cells is stable in vivo. (A) Representative HIF-1a staining in demineralized bone sections
from mice inoculated with MDA-MB-231 parental, shNT or shHIF cells. Arrows indicate HIF-1a positive nuclei. Scale bar equals 50 mm. Staining
without primary antibody was used as negative control (Neg. Control). (B) The percentage of nuclei positive for HIF-1a was calculated in three non-
overlapping fields at 4006magnification for each mouse (n=3 per group). Results are the mean 6 SEM number of HIF-1a positive nuclei per field.
doi:10.1371/journal.pone.0006896.g006
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2ME2- and SD-208-treated mice. Significantly fewer osteoclasts
per millimeter of tumor-bone interface were present in bone
metastases from 2ME2- or SD-208-treated mice compared to
control mice (P,0.01). This number was further reduced with
combined 2ME2/SD-208 treatment (P,0.01) (Figure 13D). These
results suggest that 2ME2 and SD-208 decrease bone metastases
through combined effects to reduce osteoclasts at sites of bone
metastases, in addition to their actions on tumor cells.
Discussion
Bone metastases occur in eighty percent of patients with
advanced breast cancer. They are incurable and cause significant
morbidity, including pain, pathologic fractures, hypercalcemia,
and nerve compression syndromes due to tumor-induced osteo-
clastic bone resorption [1]. Standard bisphosphonate therapies
improve skeletal morbidity by reducing this osteolysis [44,45], but
do not cause regression of established bone metastases. The bone
microenvironment by its unique composition of growth factors
housed in the mineralized bone matrix, bone resorbing and bone
forming cells, promotes a feed-forward cycle of site-specific
metastasis through high concentrations of growth factors, such
as TGF-b [2], and local hypoxia [46]. Active TGF-b in bone [2]
promotes bone metastases by increasing tumor production of
factors that stimulate osteoclastic bone resorption and tumor
growth [6,7]. TGF-b-regulated factors, such as CTGF, IL-11,
CXCR4 [13,26], and MMP-1 [24,25] are involved in multiple
steps of the metastatic cascade, including invasion, homing,
angiogenesis, and osteolysis [5] and constitute a gene signature
for tumors that metastasize preferentially to bone [8] (Table 1).
The bone microenvironment is also hypoxic [19]. Hypoxia
activates signaling through HIF-1a which, like TGF-b, increases
many of the factors that promote the feed-forward metastatic
cycle. Although previous studies have shown that both HIF-1a and
TGF-b signaling pathways are important in bone metastases,
interactions between these factors have not been reported. The
aim of these studies was to determine whether TGFb and hypoxia
act synergistically or work redundantly to promote bone
metastases.
We first investigated interactions between the pathways in vitro
by analyzing changes in gene expression in MDA-MB-231 breast
cancer cells treated with TGF-b and 1% O2. Of 16 candidate
genes, only two were increased by TGF-b and hypoxia: VEGF
and CXCR4. VEGF, but not CXCR4, mRNA was additively
increased by combined treatment with TGF-b and 1% O2, and
Figure 7. HIF-1a knockdown decreases tumor angiogenesis at sites of bone metastases in mice. (A) Representative sections from mice
with bone metastases stained for the endothelial cell marker CD31. Arrows indicate CD31+ vessels. Scale bar equals 50 mm (B) The number of vessels
in bone metastases was counted in three non-overlapping fields at 2006magnification per mouse (n=3 per group). Results are expressed as the
mean 6 SEM number of vessel per tumor area. * P,0.05, ** P,0.01, **** P,0.001, using a one-way ANOVA with a Newman-Keuls multiple
comparison test.
doi:10.1371/journal.pone.0006896.g007
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by combined treatment. Previous studies of VEGF in mouse
macrophages showed increased promoter activity in response to
TGF-b and hypoxia and to overexpression of HIF-1a/b and
Smads3/4 in vitro [47]. Elements responsible for TGF-b and
hypoxia response were localized in the proximal region of the
mouse VEGF promoter and homolog sites were identified in the
human VEGF promoter [48]. The study demonstrated that TGF-
b and hypoxia signaling directly crosstalk to regulate the
expression of VEGF in macrophages [47]. The data here suggest
that VEGF is regulated similarly by TGF-b and hypoxia in human
MDA-MB-231 cells. An HRE located 1.3 kb from the transcrip-
tion start site in the human CXCR4 promoter was found to
mediate its response to hypoxia. Mutation of either of two putative
SBEs did not significantly inhibit TGF-b-stimulated CXCR4
promoter activation. The results suggest that TGF-b regulates
CXCR4 through other SBEs in the promoter that were not tested
here.
MDA-MB-231 cells did not show significant additive responses
to TGF-b and hypoxia for the other 14 genes examined, but other
targets could be responsive. Therefore we used a comprehensive
approach to genetically approach to inhibit the pathways in the
tumor cells by expression of HIF-1a shRNA and a dominant-
negative TbRII, which then were analyzed an in vivo bone
metastasis model. This approach permits assessment of the tumor
autonomous effects of hypoxia and TGF-b, separate from their
roles in the metastatic microenvironment. Knockdown of HIF-1a
mRNA in MDA-MB-231 breast cancer cells decreased osteolytic
Figure 8. HIF-1a knockdown and TGF-b blockade decreases VEGF and CXCR4 mRNA expression in vitro. (A) MDA-MB-231 dominant-
negative TbRII expressing cells (DNRII) were transfected with a pLKO.1 vector expressing a non-target shRNA (DNRII/shNT#2 and #4) or an shRNA
against HIF-1a (DNRII/shHIF#22 and #26) were cultured 6 1% O2 during 6 h. Total RNA was extracted and mean 6 SEM expression of HIF-1a was
measured using semi-quantitative RT-PCR (n=3). * P,0.05 compared to parental (P), using an unpaired Student’s t test. (B) Proteins were extracted
from treated cells and HIF-1a level was assayed by Western-blotting. a-tubulin was used as loading control. (C) MDA-MB-231 parental cells (P) and
DNRII clones were treated 6 TGF-b (5 ng/mL) for 2 h. Proteins were extracted and analyzed for phosphorylated Smad2 (pSmad2) and total Smad2 by
Western-blotting. (D) MDA-MB-231 parental cells (P) and DNRII clones transfected with pGL3-(CAGA)9 and phRL-CMV plasmids were treated 6 TGF-b
(5 ng/mL) during 24 h before measuring dual-luciferase activity. Results are expressed as the mean 6 SEM of the relative luciferase activity (n=3).
**** P,0.001, using an unpaired Student’s t test. (E) Total RNA was extracted from MDA-MB-231 parental (P) and DNRII clones treated 6 TGF-b (5 ng/
mL) and 6 1% O2 during 24 h. Mean 6 SEM VEGF and CXCR4 expression was measured using semi-quantitative RT-PCR (n=3). * P,0.05, ** P,0.01,
*** P,0.005, using an unpaired Student’s t test.
doi:10.1371/journal.pone.0006896.g008
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HIF-1a did not yield a corresponding decrease in tumor burden at
time of death. Tumor burden in mice euthanized at the same time
point could not be compared in this survival experiment as mice
bearing shHIF bone metastases lived significantly longer than the
control groups. It is possible that knockdown of HIF-1a decreases
osteolytic lesion development without affecting the rate of tumor
growth in bone. However, this is unlikely as previous studies
demonstrated that inhibition of hypoxic signaling by a dominant-
negative HIF-1a decreased osteolytic bone destruction and tumor
burden in mice euthanized at the same time point, while a
constitutively active HIF had the opposite effect [46]. Knockdown
of HIF-1a had no effect on cell proliferation in vitro, but it
decreased primary tumor take and growth in the mammary fat
pad in our experiments. Consistent with our results, Liao et al.
reported that conditional deletion of HIF-1a from the mammary
epithelium in transgenic mice delayed onset of spontaneous breast
tumors and retarded their growth [49].
Together, our in vitro and in vivo results suggest that HIF-1a
promotes bone metastases by regulating factors such as CXCR4,
which promotes tumor cell homing to bone [50] and VEGF,
which promotes angiogenesis. HIF-1a knockdown in MDA-MB-
231 cells decreased CXCR4 expression in vitro and inhibited bone
metastasis in vivo, with no difference in metastasis to other organs,
Figure 9. Combined HIF-1a knockdown and TGF-b blockade provides no further benefit in mice with bone metastases. (A)
Representative x-ray images from hindlimbs of mice 4 weeks post inoculation with MDA-MB-231 parental, shNT#3, shHIF#3, DNRII, DNRII/shNT#2
and DNRII/shHIF#22 cells. Arrows indicate osteolytic lesions. (B) Osteolytic lesion area measured on radiographs of hindlimbs and forelimbs of mice
with bone metastases. Results are expressed as the mean area 6 SEM per mouse (n=6–11 per group). * P,0.001 compared to parental and { P,0.05
compared to shNT#3 using a two-way ANOVA with a Bonferroni post-test at 3 weeks. (C) Kaplan-Meyer analysis of mouse survival. * P,0.001
shHIF#3 and DNRII compared to Parental and { P,0.005 shHIF#3 compared to shNT#3 using a Logrank test. (D) Tumor burden in hindlimbs was
measured by quantitative histomorphometry. Results are expressed as the mean 6 SEM area per bone. A one-way ANOVA with a Newman-Keuls
multiple comparison test showed no significant differences (N.S.) between groups.
doi:10.1371/journal.pone.0006896.g009
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1a knockdown may specifically inhibit skeletal metastases by
blocking CXCR4-mediated homing to bone [51]. CXCR4 is more
highly expressed in human breast cancer metastases to bone than
to the lungs or brain [52]. Previous studies showed that treatment
with CXCR4 antagonists inhibited breast cancer metastasis to
bone and lung [53,54] and decreased bone destruction due to
myeloma bone metastases [55] in mice, which supports our results.
In addition, our results suggest a role for HIF-1a to regulate
interactions between tumor cells and other cells in the bone
microenvironment, such as endothelial cells. Knockdown of HIF-
1a in MDA-MB-231 cells decreased VEGF expression in vitro, and
inhibited tumor angiogenesis at sites of bone metastasis in vivo,a s
demonstrated by CD31 staining for endothelial cells. There was
no difference in the number of vessels in shHIF mammary fat pad
tumors compared to parental and shNT control tumors (data not
shown). The results suggest that knockdown of HIF-1a specifically
inhibits vessel formation within the hypoxic bone microenviron-
ment, which may contribute to decreased bone metastasis in the
mice. Consistent with this, treatment with a VEGF neutralizing
antibody decreased tumor angiogenesis and osteolytic bone
metastases in rats [56,57].
Inhibition of either HIF-1a or TGF-b signaling in the tumor
cells by shRNA knockdown or expression of a dominant-negative
TbRII [6] decreased osteolytic lesion area and increased survival
of mice with bone metastases compared to those bearing control
cells. However, there was no additional survival benefit or
reduction in lesion area with combined inhibition of these
pathways. The results suggest that the two signaling pathways
function in parallel and independently of one another in tumor
Figure 10. Preventive treatment with the HIF-1a inhibitor 2ME2 inhibits bone metastases in mice. (A) Representative 4-week x-rays from
mice inoculated with MDA-MB-231 cells and treated 6 2ME2 (150 mg/kg), arrows indicate osteolytic lesions. Osteolytic lesion area was measured on
radiographs of hindlimbs and forelimbs of mice with bone metastases. Results are expressed as the mean 6 SEM area per mouse (n=10–12 per
group). * P,0.01 using a two-way ANOVA with a Bonferroni post-test at 4 weeks. (B) Representative histology of tibias with tumor indicated by
arrows. Scale bar equal to 500 mm. Tumor burden in hindlimbs and humeri was measured by quantitative histomorphometry. Results are expressed
as the mean 6 SEM area per bone, analysis by unpaired Student’s t test. (C) Representative HIF-1a staining in demineralized bone metastases
sections from mice treated 6 2ME2. Arrows indicate HIF-1a positive nuclei. Scale bar equals 25 mm. The percentage of nuclei positive for HIF-1a was
calculated in three non-overlapping fields at 4006magnification for each mouse (n=6 per group). Results are the mean 6 SEM number of HIF-1a
positive nuclei per field using an unpaired Student’s t test. (D) Hypoxyprobe
TM-1 staining for tumor hypoxia in bone metastases sections. Hypoxic
regions indicated by asterisks. Staining was graded on a 1–4+ scale in three non-overlapping fields at 4006magnification per mouse (n=3 per
group). Results are the mean 6 SEM staining per field using an unpaired Student’s t test.
doi:10.1371/journal.pone.0006896.g010
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1a and TGF-b regulated many of the same prometastatic factors
independently, with few additive responses.
Genetic inhibition tests the role of tumor cell HIF-1a and TGF-
b signaling in bone metastasis but fails to address contributions
from the microenvironment. In addition, shRNA knockdowns and
dominant-negative receptors are not readily translatable to the
clinic. Therefore we used small molecule inhibitors to inhibit these
pathways systemically. 2ME2 is a naturally occurring, poorly-
estrogenic metabolite of estradiol with anti-HIF, anti-angiogenic,
and anti-microtubule properties [32,58,59]. The drug decreased
osteolytic lesion area in a 4T1 mouse model of bone metastasis
[42]. In our studies a soluble formulation of 2ME2 effectively
inhibited HIF-1a protein expression in vitro for three bone
metastatic cell lines: MDA-MB-231 breast, PC-3 prostate and
1205Lu melanoma cells, as demonstrated previously [32].
Systemic inhibition of HIF-1a by 2ME2 significantly decreased
osteolytic lesion area and reduced tumor burden in a prevention
model of MDA-MB-231 breast cancer bone metastasis, consistent
with the previous studies using 4T1 cells [42]. Staining for HIF-1a
and tumor hypoxia were decreased in bone metastases sections
from 2ME2-treated animals, demonstrating on-target effects of
2ME2 in tumor cells in vivo.
Similarly, we showed that a TbRI kinase inhibitor, SD-208,
significantly reduced osteolytic lesion area and decreased tumor
burden in mice, while increasing survival in a dose dependent
manner. SD-208 was previously shown to increase survival
following orthotopic implantation of glioma cells [31]. Inhibition
of TGF-b by another TbRI kinase inhibitor decreased breast
cancer metastases to lungs and skeleton in mice [15].
Combined treatment with 2ME2 and SD-208 significantly
decreased osteolytic lesion area on x-ray and reduced tumor
Figure 11. 2ME2 increases bone density, inhibits osteoclasts and increases osteoblasts in normal bone unaffected by tumor. (A)
Bone mineral density of the femur, tibia, and spine measured by DXA in mice treated 6 2ME2 (150 mg/kg). Results are expressed as the mean 6 SEM
% change in BMD (n=10 per group). Statistical analysis by two-way ANOVA with a Bonferroni post-test at week 4. (B) Representative histology of
tibias from mice 6 2ME2 (150 mg/kg) for 4 weeks. Trabecular bone is indicated by arrows. Scale bar equal to 500 mm. (C) Representative TRAP
staining of bone histology of the proximal tibias from the mice. TRAP+ osteoclasts (OC) are indicated by arrows. Scale bar is equal to 50 mm. (D)
Osteoclast number was measured in the distal femur and proximal tibia at 2006magnification on TRAP stained slides. Results are expressed as the
number of osteoclasts (OC) per mm
2 bone surface (BS). (E) Representative H&E stained bone histology of the proximal tibias from mice treated 6
2ME2 (150 mg/kg). Osteoblasts (OB) indicated by arrows. Scale bar is equal to 50 mm. (F) Osteoblast number was measured below the primary
spongiosa in the distal femur and proximal tibia at 2006magnification on H&E stained slides. Results are expressed as the number of osteoblasts (OB)
per mm
2 bone surface (BS).
doi:10.1371/journal.pone.0006896.g011
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either drug alone in a clinically relevant therapeutic, as well as a
prevention model of bone metastasis. Unlike the previous genetic
studies where inhibition of HIF-1a and TGF-b in tumor cells had
no additional effect, combined pharmacologic inhibition of these
pathways with 2ME2 and SD-208 provided added therapeutic
benefit, which may be due actions of the drugs on tumor cells and
other cells in the bone microenvironment, such as osteoclasts. In
the bone metastasis model, treatment with 2ME2 or SD-208 alone
decreased the number of osteoclasts at the tumor-bone interface,
which was further reduced with combined treatment. These data,
together with the additive effect of 2ME2 and SD-208 on
radiographic bone destruction induced by MDA-MB-231 cells,
suggest that these drugs may prevent tumor-induced bone
destruction by inhibiting osteoclast formation.
Systemic TGF-b blockade with SD-208 was previously shown to
have profound effects on normal bone remodeling to increase
bone mass in part by inhibiting osteoclast formation and bone
resorption, as well as to stimulate osteoblast activity and new bone
formation [60]. Here we show that 2ME2 also has direct effects on
bone to increase bone mass by decreasing osteoclasts and
increasing osteoblasts. 2ME2 is an inhibitor of HIF-1a, but the
effects of HIF-1a in bone have been shown to be complex. Mice
with a conditional deletion of HIF-1a in osteoblasts had smaller,
Figure 12. Preventive treatment with SD-208 reduces osteolytic bone lesions and increases survival. (A) Representative x-ray images
from hindlimbs of mice inoculated with MDA-MB-231 cells and treated 6 SD-208 (0.3 mg/mL or 1.0 mg/mL), arrows indicate osteolytic bone lesions.
(B) Osteolytic lesion area measured on radiographs of hindlimbs and forelimbs from mice with bone metastases. Results are expressed as the mean
area 6 SEM per mouse. **** P,0.0001 0.3 mg/mL and 1.0 mg/mL SD-208 compared to vehicle, using a two-way ANOVA with a Bonferroni post-test
at 4 weeks. (C) Representative histology of femurs with tumor indicated by arrows. Scale bar equal to 500 mm. (D) Tumor burden in hindlimbs and
humeri was measured by quantitative histomorphometry. Results are expressed as the mean 6 SEM area per bone. Statistical analysis by one-way
ANOVA with a Newman-Keuls multiple comparison test. (E) Kaplan-Meyer analysis of mouse survival analyzed using a Logrank test.
doi:10.1371/journal.pone.0006896.g012
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contrast, partial HIF-1a deficiency in mice heterozygous for HIF-
1a prevented osteoblast apoptosis and enhanced bone minerali-
zation and fracture repair [62]. Our results are consistent with the
latter study in that 2ME2 inhibits HIF-1a but increases bone mass.
In addition, HIF-1a also regulates osteoclast formation and bone
resorption [63,64] by increasing VEGF expression which
substitutes for M-CSF to promote osteoclastogenesis together with
RANKL [65,66]. 2ME2 may therefore inhibit osteoclast forma-
tion and activity indirectly by blocking HIF-1a activity and VEGF
secretion by osteoblasts. 2ME2 has also been shown to induce
apoptosis in mature osteoclasts [42], and may have other effects in
bone, as we show here. Importantly, we observed no deleterious
effects of these drug treatments on the bones of animals. Unlike
most current cancer therapies, including aromatase inhibitors,
which cause bone loss [67], 2ME2 and SD-208 have bone-sparing
effects that may contribute the beneficial effect on bone metastases
[60,68].
Our data establish that hypoxia and TGF-b signaling pathways
regulate tumor-secreted factors such as CXCR4 which promotes
tumor cell homing to the bone [50], and VEGF which stimulates
tumor angiogenesis and increases both osteoclast [65,69] and
osteoblast activity [61]. Genetic inhibition of either HIF-1a or
TGF-b in tumor cells provides proof of principle that these
signaling pathways promote bone metastasis through tumor-
autonomous effects. Systemic inhibition with 2ME2 or SD-208
also decreased bone metastases, while combined treatment
provided additional benefit through effects on the tumor cells, as
well as the bone microenvironment. Thus, combination therapy
with inhibitors of hypoxia and TGF-b may significantly improve
treatment and impact survival of patients with bone metastases,
and provide a welcome addition to current armamentarium for
bone metastases.
Materials and Methods
Ethics statement
Animal protocols were approved by the Institution Animal Care
and Use Committee at the University of Virginia and were in
accordance with guidelines from the U.S. Public Health Service
Policy on Humane Care and Use of Laboratory Animals and in
compliance with the U.S. Animal Welfare Act. Female athymic
Figure 13. Combined therapeutic treatment with 2ME2 and SD-208 additively decreases bone metastases in mice. (A) Representative
x-ray images from hindlimbs of mice inoculated with MDA-MB-231 cells and therapeutically treated 6 2ME2 (150 mg/kg) and 6 SD-208 (60 mg/kg),
arrows indicate osteolytic lesions and osteolytic lesion area measured on radiographs of hindlimbs and forelimbs from mice with bone metastases.
Results are expressed as the mean area 6 SEM per mouse (n=12–14 per group). * P,0.01 SD-208 and ** P,0.001 2ME2 compared to vehicle, {
P,0.01 SD-208 and { P,0.05 2ME2 compared to SD-208 + 2ME2, using a two-way ANOVA with a Bonferroni post-test at 3 weeks. (B) Representative
histology of femurs with tumor indicated by arrows. Scale bar equal to 500 mm. (C) Tumor burden in hindlimbs and humeri was measured by
quantitative histomorphometry. Results are expressed as the mean 6 SEM area per bone. * P,0.05, **** P,0.001, using a one-way ANOVA with a
Newman-Keuls multiple comparison test. (D) Osteoclast number per mm bone surface (BS) was counted in TRAP stained bone metastases sections.
Results are expressed as mean 6 SEM OC number per millimeter BS per bone. ** P,0.01, **** P,0.001, using a one-way ANOVA with a Newman-
Keuls multiple comparison test.
doi:10.1371/journal.pone.0006896.g013
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in laminar flow isolated hoods. Autoclaved water and mouse chow
were provided ad libitum. Animals bearing human tumor
xenografts were carefully monitored for established signs of
distress and discomfort and were humanely euthanized when
these were confirmed.
Materials
Recombinant human TGF-b1 was purchased from R&D
Systems (Minneapolis, MN). 2-methoxyestradiol (2ME2) was a
gift from Entremed (Rockville, MD) and was provided as an
orally-active, nanocrystalline dispersion [43]. SD-208 was ob-
tained from Scios, Inc. (Fremont, CA) and Epichem (Murdoch,
Australia). SD-208 is a potent inhibitor of TbRI (EC50=48 nM)
whose selectivity profile for a variety of kinases has been previously
described [31]. The drug was resuspended in 1% methylcellulose
and stored at 4uC.
Cell lines
MDA-MB-231 breast cancer cells [6] were cultured in
Dulbecco’s modified Eagle’s media (DMEM) (Hyclone Laborato-
ries, Logan, UT) containing 10% heat-inactivated fetal bovine
serum (FBS) (Hyclone). HepG2 hepatocarcinoma cells (HB-8065,
ATCC, Manassas, VA) were cultured in modified Eagle’s media
(MEM) supplemented with 10% FBS, sodium pyruvate and non-
essential amino acids. PC-3 prostate cancer cells (CRL-1435,
ATCC) were cultured in RPMI with 10% FBS. 1205Lu
melanoma cells were from Dr. Alain Mauviel, Institut National
de la Sante et de la Recherche Medicale, Paris, France [13]. The
cells were grown in a composite medium (W489) consisting of
three parts of MCDB153 and one part of L15 supplemented with
4% FBS. Cells were maintained at 37uC with 5% CO2 in a
humidified chamber. Hypoxia treatments were performed by
placing tissue culture flasks in a modular incubator chamber
(model MC-101, Billups-Rothenberg Inc., Del Mar, CA), flushed
with premixed 94% N2,5 %C O 2,1 %O 2 and maintained in a
conventional tissue culture incubator.
Preparation of stable clones
Parental MDA-MB-231 cells were transfected with a pLKO.1
plasmid coding an shRNA against HIF-1a (TRCNo.
TRCN0000003810, MISSIONH shRNA, Sigma, St. Louis, MO)
using FuGENE HD (Roche, Nutley, NJ). Cells transfected with a
non-target shRNA control vector (SHC002, MISSIONH shRNA,
Sigma) were used as a control. Single clones were selected by
limiting dilution in the presence of puromycin (Invitrogen, San
Diego, CA). Knockdown of HIF-1a mRNA and protein were
confirmed by semi-quantitative RT-PCR and Western blot
analysis. Clones were retested for stability (.80% knockdown)
after culture in the absence of puromycin for 60 days. Two non-
target controls (shNT) and two HIF-1a knockdown (shHIF) clones
were selected for further study.
The MDA-MB-231 clonal line, MDA/TbRIIDcyt, which stably
expresses a cytoplasmically truncated type II TGF-b receptor [6],
here referred to as dominant-negative receptor II (DNRII), was
transfected to express either non-target or HIF-1a shRNA. Single
cell clones were isolated, selected for resistance to G418 (Alexis
Biochemicals, San Diego, CA) and puromycin, and tested for
stable knockdown of HIF-1a as described previously. Stable
DNRII expression and blockade of TGF-b signaling were
confirmed by Western blot for phosphorylated Smad2. Two
DNRII/ shNT and two DNRII/shHIF clones were selected for in
vivo and in vitro experiments.
MTT assay
Cellproliferation wasassayed by MTT assay.Cellswereplatedat
a density of 1000 cells/well in 96-well plates. MTT reagent (20 ml,
5 mg/ml) (Calbiochem, San Diego, CA) was added to each well.
After a 5 h-incubation at 37uC, 100 mL of 0.01M HCL containing
10%SDSwereadded tolyse the cellsandthe platewasincubatedat
37uC for an additional 16 h. Absorbance was measured at 570 nm
using a Synergy
TM HT spectrophotometer (Bio-tek, Winooski, VT).
Semi-quantitative RT-PCR
MDA-MB-231 cells were seeded in 24-well plates (10
5 cells/
well). Forty-eight hours later, cells were starved overnight in basal
DMEM media, then treated 6 TGF-b1 (5 ng/mL) in DMEM-
FBS (1%) and cultured in 20% or 1% O2 for 24 h. Cells were
rinsed in PBS and then lysed in Trizol (Invitrogen) for RNA
extraction. Briefly, chloroform was added to cell lysates. Samples
were centrifuged (12,000 g, 15 min, 4uC) and the upper aqueous
phase was collected. One volume of 70% ethanol was added, then
sample was loaded on an RNeasy mini spin column (Qiagen,
Valencia, CA) and total RNA was isolated according to
manufacturer’s instructions. DNase I treatment was performed
to remove genomic DNA contamination, and RNA integrity was
assessed on agarose gels. RNA (500 ng per sample) was reverse
transcribed using Superscript II (Invitrogen) according to the
manufacturer’s instructions with anchored oligo(dT) (Abgene,
Rochester, NY) for priming. The resulting cDNAs were prepared
for semi-quantitative real-time PCR using QuantiTect SYBR
Green PCR Kit (Qiagen) and analyzed in a MyiQ
TM Single-Color
Real-Time PCR Detection System (BioRad, Hercules, CA) for 40
cycles (95uC for 1 min, 58uCo r6 0 uC for 30 s, 72uC for 30 s) after
an initial 15-min incubation at 95uC. Primers were optimized for
real-time PCR (amplification efficiency 100 6 5%). Primer
sequences are listed in Table S1. Target gene expression was
normalized against the housekeeping gene for the ribosomal
protein L32, and data were analyzed using the DDCt method.
Western blot analysis
MDA-MB-231 cells were plated in 12-well plates (2610
5 cells/
well). Forty-eight hours later, cells were serum starved overnight in
basal DMEM, then cultured in DMEM-FBS (1%) for duration of
treatment. Hypoxia treatments were performed by culturing in
1%O2 for 6 h. TGF-b1 (5 ng/mL) treatment was for 2 h. Cells
were washed once with PBS, lysed in 200 ml SDS-loading buffer,
and heated to 95uC for 5 min. Samples were loaded onto a 10%
polyacrylamide gel and electrophoresis was performed using a
Mini Trans-BlotH cell (BioRad, Hercules, CA). Proteins were
transferred onto a Hybond
TM-P membrane (GE Healthcare,
Waukesha, WI) using a Mini-PROTEANH Cell transfer system
(BioRad). Membranes were blocked in TBS-T-5% milk for 1 h,
incubated overnight with the primary antibody and for 1 h with
the secondary antibody. Antibody detection was performed using
Immobilon
TM Western Chemiluminescent HRP Substrate (Milli-
pore, Billerica, MA) according to the manufacturer’s directions
and signal was visualized on radiographic film. Antibodies used
include HIF-1a (BD Biosciences, San Jose, CA), phospho-Smad2
(Ser465/467) and Smad2 (Cell Signaling, Danvers, MA); a-tubulin
(Sigma) was used as a control. Anti-mouse IgG (Fab specific) and
anti-rabbit IgG secondary antibodies conjugated to peroxidase
were purchased from Sigma.
Dual-luciferase assays
Cells were transfected with pGL3-luciferase constructs contain-
ing either the (CAGA)9 [70], VEGF or CXCR4 promoter using
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binding elements. The 2.6 kb human CXCR4 promoter was from
Dr. Robert Strieter, University of Virginia [40,41], and the 3.3 kb
human VEGF promoter was from Dr. Lee Ellis, University of
Texas, MD Anderson Cancer Center [39]. Cells were also
transfected with a phRL-renilla plasmid (Promega, Madison, WI)
for normalization. Twenty-four hours later, cells were cultured
serum-starved in basal DMEM medium for 4 h, then treated in
the presence or absence of TGF-b1 (5 ng/mL) and 1% O2 for
24 h. Cells were washed once with PBS, lysed using Passive Lysis
Buffer (Promega), and analyzed for luciferase activity using the
Dual-Luciferase Reporter Assay System (Promega), according to
the manufacturer’s instructions on a FB12 Sirius luminometer
(Berthold Detection Systems, Oak Ridge, TN).
Plasmids
pCEP4-HIF-1a (MBA-2) was purchased from the ATCC;
pCMV-Smad2 and -Smad3 were from Dr. David Wotton
(University of Virginia); pCMV-Smad4 was from Dr. Rik Derynk
(University of California San Francisco). VEGF and CXCR4
promoter deletion mutants were generated using forward primers
containing a 59 KpnI restriction site and 39 end complementary to
the promoter (Table S2). Reverse primer (59-GTTCCATCTTC-
CAGCGGATA-39) binds a region of the luciferase coding
sequence. Promoter fragments were amplified by PCR using
PfuUltra
TM Hotstart DNA polymerase (Stratagene, La Jolla, CA).
Products were digested overnight with KpnI and XhoI, purified on
agarose gel (QIAquick Gel Extraction kit, Qiagen), and ligated
into the pGL3-luciferase vector using T4 DNA ligase (Roche)
according to the manufacturer’s instructions. QuikChangeH II
Site-Directed Mutagenesis kit (Stratagene) was used to mutate
putative Smad-binding (SBE) and hypoxia response (HRE)
elements in the VEGF and CXCR4 promoters. Primers were
designed using the QuikChangeH Primer Design Program
(Stratagene) and mutagenesis performed according to the
manufacturer’s protocol.
VEGF enzyme-linked immunosorbant assays
MDA-MB-231 parental cells and clones were plated in 12-well
plates (2610
5 cells/well) and grown for 48 h. After 4 h serum
starvation, cells were treated 6 TGF-b1 (5 ng/mL) in DMEM-FBS
(1%) and 6 1% O2 for 24 h. Conditioned media was collected and
analyzed by ELISA assay for VEGF-A (Bender MedSystems, Inc.,
Burlingame, CA), according to the manufacturer’s instructions. Cell
number per well was used for normalization.
Flow cytometry
MDA-MB-231 parental cells and clones were plated in triplicate
in 6-well plates (5610
5 cells/well). Forty-eight hours later, cells
were trypsinized, counted, and 5610
5 cells per sample were
transferred to 5 mL tubes. Cells were centrifuged (1,000 rpm,
5 min, 4uC), washed twice with flow cytometry buffer (FCB) (2%
bovine serum albumin and 0.2% sodium azide in PBS 1X) and
incubated with phycoerythrin-conjugated CXCR4 antibody
(eBiosciences, San Diego, CA) for 30 min. Cells were washed
twice, fixed in paraformaldehyde (2% in PBS 1X, 15 min, RT)
and resuspended in FCB. A FACSCalibur flow cytometer (Becton
Dickinson, Franklin Lakes, NJ) was used for flow cytometry,
followed by analysis with FloJo software (TreeStar, Ashland OR).
In vivo protocols
Bone metastasis model. Intracardiac inoculation of tumor
cells was performed as previously described [71]. Tumor cells were
trypsinized, washed twice and resuspended in PBS to a final
concentration of 10
5 cells in 100 ml. Animals were anesthetized
with ketamine/xylazine and positioned ventral side up. MDA-
MB-231 parental or clonally-derived cells (n=12–15) were
inoculated into the left ventricle by percutaneous injection using
a 26-gauge needle.
Mammary fat pad tumor model. Four week old female
nude mice were anaesthetized with ketamine/xylazine and placed
in supine position. MDA-MB-231 parental or clonally-derived
cells (10
6 cells in 100 mL PBS; n=10 mice per cell line) were
inoculated into the upper mammary fat pad using a 27-gauge
needle. Tumor size was followed by measuring tumor diameters
with calipers three times per week and tumor volume was
calculated by the formula of an ovoid: tumor volume=4/3p6L/2
(w/2)
2, where L and w equal mid-axis length and width,
respectively.
Drug treatments. 2ME2 (150 mg/kg) or its vehicle PBS was
administered daily by i.p. injection. In the first experiment, SD-
208 was administered preventively via the drinking water (either
0.3 or 1 mg/mL) beginning two days prior to tumor inoculation.
Vehicle control animals were given water without compound. In
all subsequent experiments, SD-208 (60 mg/kg) or its vehicle 1%
methylcellulose was administered daily by oral gavage. In the
preventive protocols, drug treatment was initiated two days prior
to tumor cell inoculation and continued daily for the duration of
the study. In the therapeutic protocol, drug treatment was initiated
when osteolysis was observed on x-ray and then continued during
the duration of the study.
Radiography. Osteolytic lesions were analyzed by
radiography using a Faxitron MX-20 with digital camera
(Faxitron X-ray Corporation, Wheeling, IL). Mice were imaged
in a prone position at 16magnification and 46 when osteolytic
lesions were suspected. Osteolytic lesion area was quantified using
MetaMorph software (Universal Imaging Corporation,
Dowingtown, PA).
Bone mineral density (BMD) measurement. BMD was
performed on live mice using a GE Lunar PIXImus II (GE
Healthcare) mouse densitometer (Faxitron X-ray Corporation).
Measurements were performed one time/week throughout the
experiment. The densitometer was calibrated with a plastic
embedded murine phantom before use. Mice were anesthetized,
placed on an adhesive tray in a prone position with limbs spread.
Total body measurement was performed excluding the calvarium,
mandible and teeth. A region of interest was defined at the distal
femur, proximal tibia just beneath the growth plate (12612 pixels)
and the lower lumber spine (20650 pixels). Values were expressed
as percentage change in BMD over base line in mg/cm
2.
Bone histology & histomorphometry. Forelimbs,
hindlimbs, and spine of the mice were collected upon euthanasia
and fixed in 10% neutral buffered formalin for 48 h and
decalcified in 10% EDTA for 2 weeks. After decalcification
tissues were processed in a Shandon Excelsior automated tissue
processor (Thermo Fisher Scientific, Waltham, MA) and
embedded in paraffin wax for sectioning. Longitudinal, mid-
sagittal sections 3.5 mm in thickness from the tibia, femur and
lumbar spines were cut using an automated Microm HM 355 S
microtome (Thermo Fisher Scientific). Tissue sections were stained
with hematoxylin and eosin (H&E) and prepared for
histomorphometric analysis. All sections were viewed on a Leica
DM LB compound microscope (Leica Microsystems,
Bannockburn, IL) with a Q-Imaging Micropublisher Cooled
CCD color digital camera (Vashaw Scientific Inc., Washington,
DC). Images were captured and analyzed using MetaMorph
software (Universal Imaging Corporation). Tumor burden per
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calculated at the tibia, femur and humerus at 506magnification
on H&E stained sections, as previously described [72]. Osteoclast
number at the tumor-bone interface (OC/mm bone surface) in the
femur, tibia and humerus was measured on TRAP stained slides at
2006magnification. For normal bone, osteoblast (OB) number
and osteoclast (OCL) number at the bone surface were measured
in the distal femur and proximal tibia at 2006magnification on
H&E and TRAP stained slides, respectively.
Hypoxyprobe
TM-1 staining for tumor hypoxia. For
assessment of tumor hypoxia, mice were injected 2 h prior to
euthanasia with pimonidazole (60 mg/kg i.p.) and sections stained
with Hypoxyprobe
TM-1 kit (Natural Pharmacia International,
Inc., Burlington, MA) according to the manufacturer’s
instructions. Tumor hypoxia in bone metastases tumor sections
was scored semi-quantitatively on a 1–4 + scale, based on the
percentage of positively stained tumor within a 4006field: grade
1: 25% staining, 2: 50%, 3: 75%, and 4: 100%.
Immunohistochemistry. Immunohistochemical analysis
was performed on decalcified paraffin-embedded tissue sections.
Antibodies against HIF-1a and CD31 were purchased from BD
Biosciences. All staining was performed using VECTASTAINH
Elite ABC kit (Vector Laboratories, Burlingame, CA). Slides were
stained using a 3,3, diaminobenzidine substrate kit (Vector
Laboratories) and counterstained with hematoxylin. HIF-1a and
CD31 staining were quantified by the percentage of positively
staining nuclei per 4006 field and number of vessels per 2006
field, respectively. Three or more fields per animal were analyzed
and averaged. Averages for 3 or more animals per group were
compared.
TUNEL assay. Tumor cell apoptosis was analyzed in bone
metastases tissue sections using the DeadEnd
TM Colorimetric
TUNEL system (Promega), according to the manufacturer’s
instructions.
Statistical Analyses
In Vivo. All data were analyzed with the use of Graphpad
Prism v4.0 software (GraphPad Software, Inc., La Jolla, CA).
Differences in osteolytic lesion area between clones and treatment
groups were analyzed by two-way ANOVA. Histomorphometry
for tumor burden and osteoclast number was analyzed by one-way
ANOVA and Tukey’s or Newman-Keuls multiple comparison
test. Kaplan-Meier survival curve data was analyzed by a Logrank
test. All the results were expressed as mean 6 SEM, and p,0.05
was considered significant.
In Vitro. All data were analyzed with the use of Graphpad
Prism v4.0 software (GraphPad Software, Inc., La Jolla, CA).
Samples were analyzed in triplicate for RT-PCR, dual-luciferase
assays, ELISA, and flow cytometry and statistics analyzed by
unpaired t-test. Results are expressed as mean 6 standard
deviation, and p,0.05 was considered significant.
Immunostaining was analyzed by one-way ANOVA or unpaired
t-test.
Supporting Information
Table S1 Sequences of primers for human genes analyzed by
semi-quantitative RT-PCR.
Found at: doi:10.1371/journal.pone.0006896.s001 (0.04 MB
DOC)
Table S2 PCR primer sequences for 59 to 39 deletion of VEGF
and CXCR4 promoters.
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